PROCEPT BioRobotics (Nasdaq: PRCT), today announced the international expansion of the HYDROS Robotic System, the company’s next-generation platform for delivering Aquablation therapy to treat benign ...
Procept BioRobotics today announced the international rollout of its next-generation Hydros robotic system for Aquablation ...
As of October 21, 2025, shares were priced at $34.61, down 48.57% year-over-year, and underperforming the S&P 500 by 63.63 percentage points. Procept BioRobotics is a healthcare technology company ...
PROCEPT BioRobotics PRCT is gearing up to announce its quarterly earnings on Wednesday, 2025-08-06. Here's a quick overview of what investors should know before the release. Analysts are estimating ...
Jefferies initiated coverage of Procept BioRobotics (PRCT) with a Hold rating and $95 price target The firm’s checks suggest the Hydros system launch could catalyze a replacement cycle among systems ...
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing ...
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the ...
SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative ...
SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing ...
In its fourth quarter of 2025, PROCEPT BioRobotics reported total revenue of $76.4 million, marking a 12% increase compared to the prior year, missing the consensus of $94.14 million. The increase was ...
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the top robotics to buy according to analysts. On August 7, Wells Fargo maintained its Overweight rating on PROCEPT BioRobotics Corporation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results